Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease

References

• Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD)2010 Available from: http://www.goldcopd.orgAccessed September 1, 2011
   Google Scholar
• HoggJCChuFUtokaparchSThe nature of small-airway obstruction in chronic obstructive pulmonary diseaseN Engl J Med2004350262645265315215480
   PubMed Web of Science ®Google Scholar
• ButlerJCaroCGAlcalaRDuboisABPhysiological factors affecting airway resistance in normal subjects and in patients with obstructive respiratory diseaseJ Clin Invest19603958459113806486
   PubMed Web of Science ®Google Scholar
• GrossNJCoESkorodinMSCholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjectsChest19899659849872805869
   PubMed Web of Science ®Google Scholar
• BarnesPJThe role of anticholinergics in chronic obstructive pulmonary diseaseAm J Med2004117Suppl 12A24S32S15693640
   PubMed Web of Science ®Google Scholar
• DonohueJFvan NoordJABatemanEDA 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterolChest20021221475512114338
   PubMed Web of Science ®Google Scholar
• RennardSISerbyCWGhafouriMJohnsonPAFriedmanMExtended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trialsChest1996110162708681667
   PubMed Web of Science ®Google Scholar
• van KoppenCJBlankesteijnWMKlaassenABRodrigues de MirandaJFBeldAJvan GinnekenCAAutoradiographic visualization of muscarinic receptors in pulmonary nerves and gangliaNeurosci Lett19878332372403441306
   PubMed Web of Science ®Google Scholar
• BelmonteKECholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary diseaseProc Am Thorac Soc20052429730416267352
   PubMedGoogle Scholar
• GrossNJSkorodinMSRole of the parasympathetic system in airway obstruction due to emphysemaN Engl J Med198431174214256749189
   PubMed Web of Science ®Google Scholar
• BarnesPJThe pharmacological properties of tiotropiumChest20001172 Suppl63S66S10673478
   PubMed Web of Science ®Google Scholar
• SinghSLokeYKFurbergCDInhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysisJAMA2008300121439145018812535
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
   PubMed Web of Science ®Google Scholar
• Tiotropium bromide inhalation solution [package insert]2010 Available from: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Spiriva/Spiriva.pdfAccessed June 29, 2011
   Google Scholar
• TurckDWeberWSigmundRPharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairmentJ Clin Pharmacol200444216317214747425
   PubMed Web of Science ®Google Scholar
• PratMFernandezDBuilMADiscovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicy clo[2.2.2]octane bromide (aclidinium bromide)J Med Chem200952165076509219653626
   PubMed Web of Science ®Google Scholar
• GavaldaAMiralpeixMRamosICharacterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profileJ Pharmacol Exp Ther2009331274075119710368
   PubMed Web of Science ®Google Scholar
• CasarosaPBouyssouTGermeyerSSchnappAGantnerFPieperMPreclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugsJ Pharmacol Exp Ther2009330266066819478135
   PubMed Web of Science ®Google Scholar
• CortijoJSarriaBGavaldaAMiralpeixMMorcilloEIn vitro characterization of aclidinium bromide, a novel long-acting anticholinergic: effects on isolated human bronchi [Abstract]Proc Am Thorac Soc20085A654
   Google Scholar
• NewmanSPSuttonDJSegarraRLamarcaRde MiquelGLung deposition of aclidinium bromide from Genuair, a multidose dry powder inhalerRespiration200978332232819451700
   PubMed Web of Science ®Google Scholar
• MagnussenHWatzHZimmermannIPeak inspiratory flow through the Genuair inhaler in patients with moderate or severe COPDRespir Med2009103121832183719651504
   PubMed Web of Science ®Google Scholar
• Al-ShowairRATarsinWYAssiKHPearsonSBChrystynHCan all patients with COPD use the correct inhalation flow with all inhalers and does training help?Respir Med2007101112395240117629471
   PubMed Web of Science ®Google Scholar
• JanssensWVandenBrandePHardemanEInspiratory flow rates at different levels of resistance in elderly COPD patientsEur Respir J2008311788317898020
   PubMed Web of Science ®Google Scholar
• de KoningJPvan der MarkTWCoenegrachtPMTrompTFFrijlinkHWEffect of an external resistance to airflow on the inspiratory flow curveInt J Pharm20022341–225726611839456
   PubMed Web of Science ®Google Scholar
• BrandPMeyerTWeuthenTLung deposition of radiolabeled tiotropium in healthy subjects and patients with chronic obstructive pulmonary diseaseJ Clin Pharmacol200747101335134117625157
   PubMed Web of Science ®Google Scholar
• JohnsonMANewmanSPBloomRTalaeeNClarkeSWDelivery of albuterol and ipratropium bromide from two nebulizer systems in chronic stable asthma. Efficacy and pulmonary depositionChest19899616102525460
   PubMed Web of Science ®Google Scholar
• HowarthPHWhy particle size should affect clinical response to inhaled therapyJ Aerosol Med200114Suppl 1S273411424890
   PubMedGoogle Scholar
• SentellasSRamosIAlbertiJAclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolitesEur J Pharm Sci201039528329020093184
   PubMed Web of Science ®Google Scholar
• AlbertiJMartinetASentellasSSalvaMIdentification of the human enzymes responsible for the enzymatic hydrolysis of aclidinium bromideDrug Metab Dispos20103871202121020332199
   PubMed Web of Science ®Google Scholar
• SchmidKPascualSGilEGOrtizSJansatJMPharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: a phase I, open-label, single-dose clinical trialClin Ther201032101798181221194604
   PubMed Web of Science ®Google Scholar
• Ipratropium bromide HFA inhalation solution [package insert]2010 Available from: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Atrovent+HFA/10003001_US_1.pdfAccessed June 30, 2011
   Google Scholar
• LasseterKCAubetsJChuecosFGilEGAclidinium bromide, a long-acting antimuscarinic, does not affect QT interval in healthy subjectsJ Clin Pharmacol201151692393220959525
   PubMed Web of Science ®Google Scholar
• SchelfhoutVJFerrerPJansatJMActivity of aclidinium bromide, a new long-acting muscarinic antagonist: a phase I studyBr J Clin Pharmacol201069545846420573081
   PubMed Web of Science ®Google Scholar
• ChanezPBurgePSDahlRAclidinium bromide provides long-acting bronchodilation in patients with COPDPulm Pharmacol Ther2010231152119683590
   PubMed Web of Science ®Google Scholar
• JansatJMLamarcaRde MiquelGSchrodterAMiletzkiBGurniakMSafety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participantsJ Clin Pharmacol200949101239124619592595
   PubMed Web of Science ®Google Scholar
• JonesPWRennardSIAgustiAEfficacy and safety of once-daily aclidinium in chronic obstructive pulmonary diseaseRespir Res2011125521518460
   PubMed Web of Science ®Google Scholar
• JoosGFSchelfhoutVJPauwelsRABronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patientsRespir Med2010104686587220044242
   PubMed Web of Science ®Google Scholar
• MaltaisFCelliBCasaburiRAclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPDRespir Med2011105458058721183326
   PubMed Web of Science ®Google Scholar
• Garcia GilEFerrerPJansatJMPharmacokinetics and safety of aclidinium bromide, a novel long-acting, inhaled anticholinergic, in healthy subjects [Abstract]Eur Respir J200832Suppl 52642S
   Google Scholar
• CortijoJMataMMilaraJAclidinium inhibits cholinergic and tobacco smoke-induced MUC5AC in human airwaysEur Respir J201137224425420525722
   PubMed Web of Science ®Google Scholar
• CaramoriGCasolariPDi GregorioCMUC5AC expression is increased in bronchial submucosal glands of stable COPD patientsHistopathology200955332133119723147
   PubMed Web of Science ®Google Scholar
• InnesALWoodruffPGFerrandoREEpithelial mucin stores are increased in the large airways of smokers with airflow obstructionChest200613041102110817035444
   PubMed Web of Science ®Google Scholar
• DameraGJiangMZhaoHAclidinium bromide abrogates allergen- induced hyperresponsiveness and reduces eosinophilia in murine model of airway inflammationEur J Pharmacol20106491–334935320868661
   PubMed Web of Science ®Google Scholar
• GwiltCRDonnellyLERogersDFThe non-neuronal cholinergic system in the airways: an unappreciated regulatory role in pulmonary inflammation?Pharmacol Ther2007115220822217597218
   PubMed Web of Science ®Google Scholar
• WesslerIKKirkpatrickCJThe non-neuronal cholinergic system: an emerging drug target in the airwaysPulm Pharmacol Ther200114642343411782122
   PubMed Web of Science ®Google Scholar
• ProfitaMGiorgiRDSalaAMuscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patientsAllergy200560111361136916197467
   PubMed Web of Science ®Google Scholar
• MaesenFPSmeetsJJSledsensTJWaldFDCornelissenPJTiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study GroupEur Respir J199589150615138575576
   PubMed Web of Science ®Google Scholar
• VestboJVogelmeierCCreemersJFalquesMRiberaAGilEGOnset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPDCOPD20107533133620854047
   PubMedGoogle Scholar
• JonesPWSt George’s Respiratory Questionnaire: MCIDCOPD200521757917136966
   PubMedGoogle Scholar
• CasaburiRFactors determining constant work rate exercise tolerance in COPD and their role in dictating the minimal clinically important difference in response to interventionsCOPD20052113113617136973
   PubMedGoogle Scholar
• MaltaisFHamiltonAMarciniukDImprovements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPDChest200512831168117816162703
   PubMed Web of Science ®Google Scholar
• O’DonnellDEFlugeTGerkenFEffects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPDEur Respir J200423683284015218994
   PubMed Web of Science ®Google Scholar
• O’DonnellDESciurbaFCelliBEffect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPDChest2006130364765616963658
   PubMed Web of Science ®Google Scholar